Since the MCM3 protein is involved in cell proliferation and is consistently associated with outcome of ER+ breast cancer patients who received adjuvant endocrine therapy, we questioned whether the prognostic potential of MCM3 expression is affected by Ki67, a molecule widely used as a proliferative marker. This evidence concerns the gene ESR1 and breast cancer.